Anaemia and congestive heart failure early post-renal transplantation.
BACKGROUND
Anaemia is common following renal transplantation and is associated with the development of congestive heart failure (CHF). However the prevalence of anaemia in the first year following transplantation and the association between anaemia occurring early and the development of CHF have been understudied.


METHODS
In this study, 132 incident patients undergoing tacrolimus and mycophenolate mofetil-based renal transplantation were studied for the prevalence of, and risk factors for, anaemia and CHF in the early period post transplantation.


RESULTS
Anaemia occurred in 94.5% and 53.1% of patients at 1 week and 12 months, respectively, and was associated with allograft dysfunction, hypoalbuminaemia, higher mycophenolic acid (MPA) levels, bacterial infection and hypoalbuminaemia. The association with hypoalbuminaemia may reflect the presence of chronic inflammation post-transplantation. Of patients displaying haemoglobin <11 g/dl, 41.1% and 29.4% were treated with erythropoiesis stimulating agents (ESAs) at 1 and 12 months respectively. CHF developed in 26 patients beyond 1 month post-transplantation, with echocardiographic left ventricular systolic function preserved in all but one. CHF was associated with anaemia and lower haemoglobin, allograft dysfunction, duration of dialysis and left ventricular hypertrophy on echocardiography prior to transplantation, suggesting the aetiology of CHF may involve the interplay of diastolic cardiac dysfunction, pre-load mismatch and after-load mismatch.


CONCLUSIONS
Modification of risk factors may improve anaemia management post transplantation. Reducing the prevalence of anaemia may in turn reduce the incidence of CHF-these observations support the need for clinical trials to determine how anaemia management may impact CHF incidence.
Department of Nephrology, University Hospital Birmingham, Edgbaston, Birmingham B15, United Kingdom. richard.borrows@uhb.nhs.uk
Richard
R
Borrows
Marina
M
Loucaidou
Gary
G
Chusney
Sarah
S
Borrows
Jen Van
JV
Tromp
Tom
T
Cairns
Megan
M
Griffith
Nadey
N
Hakim
Adam
A
McLean
Andrew
A
Palmer
Vassilios
V
Papalois
David
D
Taube
D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology*; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D006333:Heart Failure / Q000209:etiology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D034141:Hypoalbuminemia / Q000209:etiology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D011446:Prospective Studies; D011994:Recombinant Proteins; D012307:Risk Factors; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
D006454:Hemoglobins; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D009173:Mycophenolic Acid; D016559:Tacrolimus